PRUNUS Therapeutics

PRUNUS Therapeutics is a Chicagoland-based biotechnology startup founded in 2016 that focuses on developing sustainable cancer therapeutics. Its primary approach involves targeting the biological differences between cancer and normal cells, particularly by focusing on detached cancer cells that exhibit anoikis resistance and anchorage-independent growth. The company’s leading candidate, internally referred to as :D, is a chemo-free agent designed to destroy cells in attachment-free conditions, such as 3D spheroids, without affecting cells in 2D monolayers. Additionally, the company explores Selective Metabolic Labeling, a technology using non-toxic small molecules to label proteins in cancer cells, aiming to overcome limitations of traditional regimens and high-cost biologics.

This development is significant for oncology, as it seeks to provide new, sustainable treatment options that improve patient outcomes and quality of life by minimizing off-target toxicity and the bystander effects often associated with conventional chemotherapy. By addressing fundamental metastatic processes and utilizing a novel mechanism of action, the company intends to offer alternatives for drug-resistant cancers. PRUNUS Therapeutics is currently in the preclinical stage, actively advancing its therapeutic candidates while navigating the inherent challenges of early-stage pharmaceutical research.